A very strange announcement at a time when the primary objective should be building investor confidence.
Key takeaways
No mention of DX3.
No mention of the pending exercise of PABO and PABOA options. I think they have given up on any financing from this source.
No indicative date for commencement of the DX1 Phase 1 clinical trail.
And most galling for shareholders under Item 6.1 it would appear they have paid the good Dr a bonus from shareholders' funds of approximately $94,000 in a year where the company went backwards, and shareholders have lost over 50% of their value. BOD please explain. How could you be so dismissive of shareholders to whom you hold a duty of care!!!!!
IMO DYOR
Clare
PAB Price at posting:
1.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)